Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin vs Venlafaxine for hot flashes in breast cancer
NCT06106529Phase 3Recruiting
- Sponsor
- Reinier de Graaf Hospital
- Start
- Oct 2024
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxybutynin in hot flashes, sponsored by Reinier de Graaf Hospital. Started Oct 2024; status: recruiting.
02
Drugs
oxybutynin
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT06106529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106529.